Insulin signaling pathways in a patient with insulin resistance of difficult management - a case report
© Taboada et al; licensee BioMed Central Ltd. 2009
Received: 16 March 2009
Accepted: 26 November 2009
Published: 26 November 2009
Insulin signalling pathways were investigated in a 33 year-old woman with immunologic insulin resistance. Her past medical history was remarkable for intermittent use of insulin and allergic reactions to several drugs, and measure of plasma anti-insulin antibodies level corroborated the clinical suspicion of immune mediated insulin resistance (8074 nU/ml - RIA - Ref value: <60). Treatment with several immunosuppressive regimens was tried, however the results were disappointing. Possible subcellular mechanisms of insulin resistance were investigated by performing analysis of insulin receptor and post receptor signaling in skeletal muscle biopsy. The expression of insulin receptor (IR), insulin receptor substrate 1 (IRS-1) and glucose transporter 4 (GLUT-4) was evaluated in total extract from muscle tissue by Western blotting. Basal IR, IRS-1 and GLUT-4 expression was detected, however receptor autophosphorylation was not observed. A study of translocation of GLUT-4 to plasma membrane showed that tissue presented low levels of membrane-associated GLUT-4. When in vitro stimulation was undertaken, tissue was capable to be responsive to insulin. Our results suggest that even though IR expression was normally occurring, IR β-subunit tyrosine kinase activity in muscle was down-regulated leading to alterations in insulin post receptor signaling. Consistent with normal insulin receptor and post receptor signaling, our results were compatible with decreased insulin binding to IR probably due to neutralization by anti-insulin antibodies. In conclusion, this patient has immunologic insulin resistance and treatment should be based on immunosuppressive drugs as tolerated.
Immunologic insulin resistance is a disorder recognized in the clinical practice for many years [1, 2]. Its pathogenesis is related to the presence of plasma anti-insulin antibodies, and patients at greatest risk are those who ever used non-human insulin and those who had a history of intermitent use of this drug . Treatment interruption and re-introduction of insulin works as a booster, a very well-known effect in the immunization practice that induces the rising of antibodies against the presented antigen. Other patients at risk for the development of anti-insulin antibodies are those with an allergic history or with auto-immune diseases .
After excluding the possibility of resistance to the subcutaneous route of administration by using the parenteral route  and making a trial of a synthetic insulin analogue , treatment is based upon immunosuppression. Many regimens have already been described as resulting in good clinical and laboratorial results but there are no consensus in the literature as to which is the best one [3–5, 7].
We hereby present a case of immunologic insulin resistance that has not responded to many therapeutic immunosuppressive interventions resulting in great anxiety for assistant physicians and leading us to investigate the possibility of a subcellular mechanism of disease.
A 33 year-old woman with diabetes for 25 years was treated with NPH insulin (0.77 U/kg/day) when she first came to our attention. She had a positive history of allergy to penicillin and no other morbidities. During her adolescence, she had been switched to oral hypoglycemiants for approximately 4 years, which made her diabetes difficult to classify.
During follow-up we were able to gradually decrease her insulin dose until she was successfully switched back to oral agents. For 11 months she was on a regimen of glyburide (10 mg bid), metformin (850 mg tid) and acarbose (50 mg tid), before being admitted with hyperosmolar non-ketotic coma.
After a prolonged hospital stay she was discharged home using NPH insulin. Over the following months, worsening glycemic control indicated progressive insulin dose increments (from 0.6 to 5.7 U/Kg/day). When 2.7 U/Kg/day was reached, we discarded all causes of secondary diabetes and plasma anti-insulin antibodies were determined (8074 nU/ml - RIA - Ref value: <60). We concluded she developed immunologic insulin resistance.
Several immunosuppressive regimens were tried such as glucocorticoids , cyclophosphamide , immunoglobulin  and plasmapheresis [5, 7] but the results were disappointing (average glycemia before: 468 mg/dl, insulin dosage: 490 U/d; average glycemia after: 450 mg/dl, insulin dosage: 450 U/d) and life-threatening infectious complications indicated immunosuppressant interruption every time.
Subcutaneous resistance to insulin was ruled out by intravenous administration during the inpatient period . Thereafter the patient was switched to Lispro  administered by continuous subcutaneous infusion.
Once insulin dose still needed to be increased, patient was started on a combination of micophenolate mophetil (1 g bid) and prednisone (40 mg/d) in an outpatient basis. After one year, insulin dose was reduced from 5.8 to 3.48 U/Kg/d and glycemic control, even if not optimum, has shown some improvement (average glycemia: 390 to < 200 md/dL). It is important to note that patient did not experience fasting hypoglycemia since severe insulin resistance developed.
We conclude that this patient has immunologic insulin resistance of difficult management. The best immunosuppressive regimen for her, in terms of improvement in glycemic control, was the combination of prednisone and micophenolate mophetil, however the results are slow as a result of the type of response to these drugs. The muscular biopsy helped to rule out a subcellular mechanism of insulin resistance that would be more difficult to treat.
The authors are greatly indebted to Prof. Sergio Atala Dib (UNIFESP) for his help in studying the anti-insulin antibodies.
- Jansen FK: Immunological tolerance against insulin. A therapeutic goal to prevent immunological complications in the diabetic patient using insulin. Med Welt. 1972, 23: 1818-19.PubMedGoogle Scholar
- Boos R: Immunological problems in diabetes mellitus. Med Klin. 1969, 64: 1492-96.PubMedGoogle Scholar
- Ganz MA, Unterman T, Roberts M, Uy R, Sahgal S, Samter M, Grammer LC: Resistance and allergy to recombinant human insulin. J Allergy Clin Immunol. 1990, 86: 45-51. 10.1016/S0091-6749(05)80122-8.View ArticlePubMedGoogle Scholar
- DiPaolo S, Giorgino R: Insulin resistance and hypoglycemia in a patient with systemic lupus erythematosus: description of antiinsulin receptor antibodies that enhance insulin binding and inhibit insulin action. J Clin Endocrinol Metab. 1991, 73: 650-657. 10.1210/jcem-73-3-650.View ArticleGoogle Scholar
- Eriksson JW, Bremell T, Eliasson B, Fowelin J, Fredriksson L, Yu ZW: Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Diabetes Care. 1998, 21: 1217-20. 10.2337/diacare.21.8.1217.View ArticlePubMedGoogle Scholar
- Lahtela JT, Knip M, Paul R, Antonen J, Salmi J: Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog Lispro. Diabetes Care. 1997, 20: 71-3. 10.2337/diacare.20.1.71.View ArticlePubMedGoogle Scholar
- Micic D, Brkic S, Kendereski a, Popovic V, Svetlana Z, Nikolic JA, Igrutinovic L, Ivanoska D, Manojlovic D, Micic J: Immunological resistance to human biosynthetic insulin - effects of immunossupression and plasmapheresis. Diabetes Res Clin Pract. 1993, 19: 83-9. 10.1016/0168-8227(93)90148-X.View ArticlePubMedGoogle Scholar
- Mandell BF: Intravenous gamma-globulin therapy. J Clin Rheumatol. 1996, 2: 317-324. 10.1097/00124743-199612000-00004.View ArticlePubMedGoogle Scholar
- Ozanne SE, Wang CL, Coleman N, Smith GD: Altered muscle insulin sensitivity in the male offspring of protein-malnourished rats. Am J Physiol. 1996, 271: E1128-E1134.PubMedGoogle Scholar
- De Freitas MS, Garcia De Souza EP, Silva SV, Kaezer AR, Vieira RS, Moura AS: Up-regulation of phosphatidylinositol 3-kinase and glucose transporter 4 in muscle of rats subjected to maternal undernutrition. Biochim Biophys Acta. 2003, 1639: 8-16.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.